Evidence map›Paper›PMID 38938724›Full record

ArticleJACC. Advances2023

Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT.

Selma Hasific, Kristian A Oevrehus, Jes S Lindholt, Anna Mejldal, Damini Dey, Jordi S Dahl, Niels Erik Frandsen, Søren Auscher, Jess Lambrechtsen, Susanne Hosbond and 5 more

Abstract read
In one paragraph

Article in JACC. Advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Current Knowledge of the Impact of Vitamin D in Coronary Artery Disease.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Selma HasificDepartment of Cardiology, University Hospital, Odense, Denmark.
Kristian A OevrehusDepartment of Cardiology, University Hospital, Odense, Denmark.
Jes S LindholtDepartment of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.
Anna MejldalDepartment of Clinical Research, OPEN, University of Southern Denmark, Odense, Denmark.
Damini DeyCedars-Sinai Medical Center, Biomedical Imaging Research Institute, Los Angeles, USA.
Jordi S DahlDepartment of Cardiology, University Hospital, Odense, Denmark.
Niels Erik FrandsenDepartment of Cardiology, University Hospital, Odense, Denmark.
Søren AuscherDepartment of Cardiology, OUH Svendborg Hospital, Svendborg, Denmark.
Jess LambrechtsenDepartment of Cardiology, OUH Svendborg Hospital, Svendborg, Denmark.
Susanne HosbondDepartment of Cardiology, Lillebaelt Hospital, Vejle, Denmark.
Dilek AlanDepartment of Cardiology, Lillebaelt Hospital, Vejle, Denmark.
Grazina UrbonavicieneDepartment of Cardiology, Regional Hospital Central Jutland, Silkeborg, Denmark.
Søren BeckerDepartment of Cardiology, Regional Hospital Central Jutland, Silkeborg, Denmark.
Lars M RasmussenDepartment of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.
Axel P DiederichsenDepartment of Cardiology, University Hospital, Odense, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Extent and progression of coronary artery calcification (CAC) are strong predictors of myocardial infarction and mortality. Objectives: This study aims to investigate if vitamin K2 and D supplementation can reduce CAC progression. Methods: A total of 389 participants were randomized to supplementation with vitamin K2 (720 μg/day) and D (25 μg/day) vs placebo in a multicenter double-blinded randomized controlled trial. The primary endpoint (progression of aortic valve calcification) has been reported. This study reports CAC progression in participants with no ischemic heart disease. CT scans were performed at baseline, 12, and 24 months. ΔCAC and coronary plaque volume were evaluated in the entire group and in 2 subgroups. A safety endpoint was the composite of myocardial infarction, coronary revascularization, and all-cause mortality. Results: In total, 304 participants (male, mean age 71 years) were identified. The intervention and placebo group both increased in mean CAC scores from baseline to 24-month follow-up (Δ203 vs Δ254 AU, Conclusions: Patients with no prior ischemic heart disease randomized to vitamin K2 and D supplementation had no significant reduction in mean CAC progression over a 2-year follow-up compared to placebo. Although the primary endpoint is neutral, differential responses to supplementation in those with CAC scores ≥400 AU and in safety endpoints are hypothesis-generating for future studies.

Indexed as

CAC scorecardiac CT scancoronary artery diseasevitamin Dvitamin K2

Identifiers

PMID38938724
PMCPMC11198368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.